Moderna (NASDAQ:MRNA) Price Target and Financial Outlook

• Cory Kasimov from Evercore ISI sets a price target of $32 for Moderna (NASDAQ:MRNA), indicating a potential upside of about 8.25%.

• Moderna is expected to report a quarterly loss of $2.97 per share, an improvement from last year's loss of $3.33 per share.

• The company's projected quarterly revenue is expected to be $113 million, a significant drop from the $241 million reported in the same quarter last year.

On August 1, 2025, Cory Kasimov from Evercore ISI set a price target of $32 for Moderna (NASDAQ:MRNA). At the time, the stock was trading at $29.56, indicating a potential upside of about 8.25%. Moderna is a biotechnology company known for its mRNA technology, particularly its COVID-19 vaccine. The company faces competition from other vaccine producers like Pfizer and Johnson & Johnson.

Moderna is set to release its second-quarter earnings results after the market closes on August 1. Analysts expect a quarterly loss of $2.97 per share, which is an improvement from last year's loss of $3.33 per share. This suggests that while the company is still operating at a loss, it is making progress in reducing its financial deficits.

The company's projected quarterly revenue is expected to be $113 million, a significant drop from the $241 million reported in the same quarter last year. This decline in revenue is largely due to decreasing sales of COVID-19 vaccines, as highlighted by the company's recent announcement to cut its global workforce by about 10% by the end of the year.

Following the announcement of workforce reductions, Moderna's shares dropped by 8.1%, closing at $29.56. The stock has fluctuated between $29.31 and $31.83 today, with a 52-week high of $91.99 and a low of $23.15. This volatility reflects the market's reaction to the company's current challenges and future prospects.

Moderna's market capitalization is approximately $11.43 billion, with a trading volume of 14.39 million shares. This indicates a significant level of investor interest, despite the company's current financial challenges. The stock's performance and future outlook will likely be influenced by its upcoming earnings report and strategic decisions.